Rosette Pharma

Rosette Pharma is a UK-based biopharmaceutical company specializing in the discovery and development of novel cannabinoid-based therapies and small molecules. The company was established by the founding leadership team of GW Pharmaceuticals, bringing decades of experience in the successful development and commercialization of cannabinoid medicines. Rosette Pharma focuses on addressing complex neurological and psychiatric disorders, including refractory epilepsy and chronic pain, through innovative drug delivery and formulation. Their pipeline includes proprietary compounds designed to optimize therapeutic efficacy while minimizing side effects compared to first-generation treatments. As a private enterprise, the company is advancing its lead candidates through preclinical and early clinical stages. The organization leverages deep scientific expertise to explore the therapeutic potential of the endocannabinoid system in various high-unmet-need indications.